Want to see PRTCY full AI Analyst Report?
PureTech Health (PRTCY) AI Stock Analysis
PureTech Health
(Other OTC:PRTCY)
The score is held back primarily by weak financial performance (recurring losses and persistent negative free cash flow) and a mixed-to-soft technical setup (below key moving averages with slightly negative MACD). These are partially offset by a constructive earnings-call outlook emphasizing an extended cash runway and sharply lower expected cash burn, while valuation remains constrained by negative earnings (negative P/E) and no dividend yield provided.
PureTech Health (PRTCY) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $389.71M
- Dividend Yield
- ―
- Average Volume (3M)
- 30.97K
- Price to Earnings (P/E)
- 167.0
- Beta (1Y)
- 0.33
- Revenue Growth
- -0.87%
- EPS Growth
- -95.55%
- Country
- US
- Employees
- 90
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
PureTech Health Business Overview & Revenue Model
Company Description
PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neurop...
How the Company Makes Money
PureTech Health’s earnings are primarily tied to value creation from its drug discovery and development activities and, where applicable, downstream commercialization. Key ways the company can generate revenue include: (1) Product revenue: if a PureT...
PureTech Health Earnings Call Summary
The call was predominantly positive, highlighting successful financing and IPO execution, clinical and regulatory progress, a strong cash runway, lower expected go-forward cash burn and an innovation pipeline ahead of its stated target. The main negatives were the material downgrade in estimated future Cobenfy proceeds, the first-half cash balance decline, higher first-half operating expenses and pending financing requirements for Gallop and Celea.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management reiterated operational runway at least through the end of 2028, excluding inflows from potential future monetization events and assuming full deployment of the additional $70 million reserved for potential future investments in Celea; PureTech level cash, cash equivalents and short-term investments were approximately $220 million at June 2026, and go-forward cash burn including overhead and innovation spend is expected to be somewhere between $30 million and $40 million a year versus roughly $90 million a year previously. Gallop intends to complete financing by the first half of next year before initiating the STRIDE-MDS trial, which is expected to enroll approximately 125 patients, with initial projections on the more conservative side indicating probably somewhat under 3 years to complete the study, with actual timing potentially more around 30 months or 33 months; the financing would support Gallop through the readout. PureTech aims to advance at least 3 opportunities to the concept stage each year, expects to share additional detail in the first half of 2027, and estimates approximately $50 million in potential future proceeds from remaining Cobenfy economic rights based on analyst consensus as of mid-August.
PureTech Health Financial Statement Overview
Summary
Overall fundamentals are weak: the income statement shows small/volatile revenue with a ~21% decline in 2025 and recurring large operating losses; cash flow is a major concern with persistently negative operating and free cash flow and further FCF deterioration in 2024–2025. The main offset is a comparatively conservative balance sheet with low leverage, though equity/assets have trended down over 2020–2025.
Income Statement
18Very NegativeBalance Sheet
64PositiveCash Flow
14Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.65M | 4.66M | 4.83M | 3.33M | 2.09M | 9.98M |
| Gross Profit | -21.90M | 4.66M | 1.26M | -1.60M | -136.81M | -100.49M |
| EBITDA | -94.99M | -61.80M | 37.38M | -11.63M | -188.91M | 26.70M |
| Net Income | -109.49M | -109.74M | 53.51M | -65.70M | -50.35M | -60.56M |
Balance Sheet | ||||||
| Total Assets | 534.71M | 534.71M | 602.63M | 693.97M | 702.65M | 946.01M |
| Cash, Cash Equivalents and Short-Term Investments | 278.89M | 278.89M | 367.31M | 327.14M | 350.10M | 465.71M |
| Total Debt | 19.76M | 19.76M | 22.36M | 25.34M | 46.87M | 52.75M |
| Total Liabilities | 229.03M | 229.03M | 194.70M | 235.74M | 155.06M | 361.86M |
| Stockholders Equity | 312.07M | 312.07M | 414.71M | 464.07M | 542.22M | 593.51M |
Cash Flow | ||||||
| Free Cash Flow | -84.82M | -85.34M | -134.38M | -106.16M | -180.97M | -163.94M |
| Operating Cash Flow | -84.81M | -85.33M | -134.37M | -105.92M | -178.79M | -158.27M |
| Investing Cash Flow | 63.05M | 63.44M | 240.89M | 68.99M | -107.22M | 197.38M |
| Financing Cash Flow | -6.30M | -6.34M | -16.96M | 78.14M | -29.83M | 22.73M |
PureTech Health Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRTCY, the sentiment is Positive. The current price of 16.64 is above the 20-day moving average (MA) of 15.27, above the 50-day MA of 15.65, and below the 200-day MA of 16.71, indicating a neutral trend. The MACD of 0.19 indicates Negative momentum. The RSI at 66.82 is Neutral, neither overbought nor oversold. The STOCH value of 100.18 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRTCY.
PureTech Health Peers Comparison
Overall Rating
PBYI84Outperform- PRTCY50Neutral
ALEC49Neutral
PRTA46Neutral
ACIU45Neutral
ARCT43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| PBYI | 84Outperform | $525.49M | 19.06 | 20.85% | ― | -2.86% | -46.26% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| PRTCY | 50Neutral | $393.99M | 166.96 | 0.14% | ― | -0.87% | -95.55% |
| ALEC | 49Neutral | $318.75M | -1.86 | -531.04% | ― | -82.91% | 6.27% |
| PRTA | 46Neutral | $425.58M | -9.89 | -14.98% | ― | 427.32% | 85.31% |
| ACIU | 45Neutral | $209.65M | -3.96 | -99.17% | ― | -33.68% | 4.48% |
| ARCT | 43Neutral | $269.73M | -2.86 | -46.54% | ― | -82.95% | -49.04% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PRTCY | Puretech Health Plc | 16.64 | -0.36 | -2.15% | |
| PBYI | Puma Biotechnology | 10.22 | 5.28 | 106.88% | |
| PRTA | Prothena Corporation | 8.21 | -2.06 | -20.06% | |
| ARCT | Arcturus Therapeutics | 9.54 | 0.90 | 10.42% | |
| ACIU | AC Immune | 2.09 | -1.34 | -39.07% | |
| ALEC | Alector | 2.05 | 0.79 | 63.35% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 22, 2026